ADMA Biologics, Inc. (ADMA) FinancialsADMAADMA Biologics, Inc.

ADMA Biologics, Inc. (ADMA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is ADMA BioManufacturing, accounting for 99.4% of total sales, equivalent to $123.64M. Other significant revenue streams include Plasma Collection Centers and Reconciliation. Understanding this composition is critical for investors evaluating how ADMA navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, ADMA Biologics, Inc. maintains a gross margin of 69.31%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 42.16%, while the net margin is 30.40%. These profitability ratios, combined with a Return on Equity (ROE) of 41.90%, provide a clear picture of how effectively ADMA converts its operational activities into shareholder value.

In the context of the broader market, ADMA competes directly with industry leaders such as COAG and KLRA. With a market capitalization of $2.09B, it holds a significant position in the sector. When comparing efficiency, ADMA's gross margin of 69.31% stands against COAG's N/A and KLRA's N/A. Such benchmarking helps identify whether ADMA Biologics, Inc. is trading at a premium or discount relative to its financial performance.

ADMA Biologics reported a gross margin of 69% in Q2 2026, showcasing strong profitability. The company also achieved an adjusted net income of $38.96 million, an 8% increase year-over-year, indicating effective cost control and market demand growth.